Pro 2013-019 (Jianfeng Group Company Bond Coupon Rate Announcement)
Release time:
2020-08-05
Stock Abbreviations: Jianfeng Group Stock Code: 600 668 Announcement No.: Pro 20 13-019
Bond Abbreviations: 13 Peak 01
Zhejiang Jianfeng Group Co., Ltd.
20 13 Corporate Bond (Phase I) Coupon Rate Announcement
Issuer Board of Directors and all directors guarantee that there are no false records, misleading statements or major omissions in the contents of this announcement, and assume individual and joint responsibility for the truthfulness, accuracy and completeness of its contents.
approved by China Securities Regulatory Commission Securities Regulatory License [ 20 13]595 , zhejiang Jianfeng Group Co., Ltd. (hereinafter referred to as "Issuer " ) was approved to publicly issue corporate bonds with a face value of not exceeding RMB 6 .9 billion. The issuer's bonds are issued in installments, of which the first installment, that is, Zhejiang Jianfeng Group Co., Ltd. 2013 corporate bonds (the first installment) (hereinafter referred to as "the current bonds"), is issued at a scale of RMB 3 .6 billion.
2013 6 February 4 , the issuer and the sponsor (lead underwriter) Zheshang Securities Co., Ltd. conducted an offline coupon rate inquiry to institutional investors. According to the inquiry results, the issuer and the sponsor (lead underwriter) Zheshang Securities Co., Ltd. fully negotiated and carefully judged, the coupon rate of Zhejiang Jianfeng Group Co., Ltd. 2013 corporate bonds (Phase I) was finally determined to be 4.90% . The issuer of
will make an online public offering to public investors on , 2013 , , , , according to the above coupon rate (the online offering code is "751975 ", referred to as "13 peak 01 "), it was issued to institutional investors on 2013 6 5 , 2013 6 April 6 and 2013 6 7 . For specific subscription methods, please refer to Zhejiang Jianfeng Group Co., Ltd. (Phase I) published on "china securities journal"#, "shanghai securities news" and the website of Shanghai Stock Exchange (http://www.sse.com.cn ) on ,#, June , 117 , 2013 issue Announcement ". is hereby announced.
Issuer: Zhejiang Jianfeng Group
Co., Ltd.Sponsor (Lead Underwriter): Zhejiang Securities Co., Ltd.
2013September
5
More information
Publicity of Environmental Protection Acceptance for Completion of Kiln End Flue Gas Desulfurization Project of daye peak cement co., ltd. According to the requirements of the Interim Measures for Environmental Protection Acceptance for Completion of Construction Projects (No.4 [2017] of the State Environmental Regulations) issued by the Ministry of Environmental Protection, the environmental protection acceptance information of "Kiln End Flue Gas Desulfurization Project" of daye peak cement co., ltd. is now publicized. Basic Information of 1. Project Project Name: Kiln End Flue Gas Desulfurization Project Construction Unit: daye Jianfeng Cement Co., Ltd. Project Construction Location: Yongguang Village, Baoan Town, daye city, nature of the project in the existing plant area of daye Jianfeng Cement Co., Ltd.: The construction content of the technological transformation project is: This technological transformation project is mainly to build a wet desulfurization system for kiln end gas of the company's existing 4000t cement clinker production line, adopting limestone-gypsum wet flue gas desulfurization process. The project covers a total area of 500 m2, with a new construction area of about 450 m2. It mainly builds desulfurization complex building, flue gas system, SO2 absorption system, limestone powder conveying and limestone slurry preparation system, process water system, gypsum dehydration system and supporting pipelines. Power supply, water supply, compressed air and other public works rely on the existing plant. Total investment and environmental protection investment: the total investment of the project is 10.37 million yuan, all of which are environmental protection investment. The project was entrusted to Huangshi Yangtze River Environmental Engineering Design and Research Institute to carry out environmental impact assessment in September 2017. On November 16, 2017, Daye Municipal Environmental Protection Bureau issued a reply with YEHAN [2017] No. 354. Implementation of 2. environmental protection measures The scope of this acceptance is the flue gas desulfurization system and supporting facilities at the end of the kiln. (1) Exhaust gas pollution
2020
07-31
Spike New Drug Approved for Registration
On April 16, Jianfeng Pharmaceutical Company received the approval and issuance of Olopatadine Hydrochloride Eye Drops "Drug Registration Approval" (approval number: 2019S00296) approved by the State Drug Administration. Olopatadine hydrochloride eye drops is mainly used to treat the signs and symptoms of allergic conjunctivitis. It is a mast cell stabilizer and a relatively selective histamine H1-receptor antagonist. It can inhibit type I immediate allergic reactions in vivo and in vitro experiments. At present, the product has been included in the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog (2017 Edition)" and classified as Class B. According to the relevant data of IMS database, in 2018, the global sales of olopatadine hydrochloride eye drops were about 0.37 billion US dollars, and the sales in China were about 10.232 million US dollars. Spike Pharmaceuticals already has the corresponding production line, this time to obtain the registration approval, marking Spike Pharmaceuticals has the qualification to carry out the production and sales of olopatadine hydrochloride eye drops, will further enrich the product line of Spike Pharmaceuticals, help to enhance the competitiveness of the company's pharmaceutical business. (Xia Yingpin)
2020
07-31
Spike New Drug Approved for Registration
On April 16, Jianfeng Pharmaceutical Company received the approval and issuance of Olopatadine Hydrochloride Eye Drops "Drug Registration Approval" (approval number: 2019S00296) approved by the State Drug Administration. Olopatadine hydrochloride eye drops is mainly used to treat the signs and symptoms of allergic conjunctivitis. It is a mast cell stabilizer and a relatively selective histamine H1-receptor antagonist. It can inhibit type I immediate allergic reactions in vivo and in vitro experiments. At present, the product has been included in the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog (2017 Edition)" and classified as Class B. According to the relevant data of IMS database, in 2018, the global sales of olopatadine hydrochloride eye drops were about 0.37 billion US dollars, and the sales in China were about 10.232 million US dollars. Spike Pharmaceuticals already has the corresponding production line, this time to obtain the registration approval, marking Spike Pharmaceuticals has the qualification to carry out the production and sales of olopatadine hydrochloride eye drops, will further enrich the product line of Spike Pharmaceuticals, help to enhance the competitiveness of the company's pharmaceutical business. (Xia Yingpin)
2020
07-31
Contact Us
No. 88 Wujiang East Road, Jinhua City, Zhejiang Province, China
Tel: +86-579-82326868
Fax : +86-579-82324666
©2023 Zhejiang Jianfeng Group Co., Ltd. Powered by: www.300.cn SEO Business License
SAF Coolest v1.2 设置面板 SHJSS-AHDB-FSSQE-ZSW
无数据提示
Sorry, the current column has no content !
You can view other columns or return to Home Page